TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7485941

Group type: EXPERIMENTAL
Intervention: dopexamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: dobutamine
Number of subjects: 16
Study: 2305976

Group type: EXPERIMENTAL
Intervention: PCEA (Patient-Controlled Epidural Analgesia)
Number of subjects: 58

Group type: COMPARATOR
Intervention: CIT (Conventional Intermittent 'Top-Up' Injections)
Number of subjects: 58
Study: 7272395

Group type: EXPERIMENTAL
Intervention: Finger temperature biofeedback
Number of subjects: 12

Group type: COMPARATOR
Intervention: Guided imagery
Number of subjects: 12
Study: 30226009

Group type: EXPERIMENTAL
Intervention: Self-hypnosis (3 sessions)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-hypnosis (habitual users)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 120
Study: 28374969

Group type: EXPERIMENTAL
Intervention: Spontaneous-timed (ST) mode
Number of subjects: 13

Group type: COMPARATOR
Intervention: Spontaneous (S) mode
Number of subjects: 13
Study: 25747263

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a dose prescription of 35 Gy in five fractions
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Re-optimized plans
Number of subjects: 70
Study: 24220385

Group type: EXPERIMENTAL
Intervention: Miniscrews in the retromolar area
Number of subjects: 19

Group type: COMPARATOR
Intervention: Miniscrews in the posterior area of the maxillary
Number of subjects: 19
Study: 20359590

Group type: EXPERIMENTAL
Intervention: Delay to PCI >24 h
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Delay to PCI <8 h
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Delay to PCI 8 to 24 h
Number of subjects: 7749
Study: 18991820

Group type: EXPERIMENTAL
Intervention: Antiatherogenic diet with sour milk product Danacor enriched with phytosterols
Number of subjects: 0
Study: 15665710

Group type: EXPERIMENTAL
Intervention: HIV-uninfected children
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 1118
Study: 12845486

Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 53

Group type: COMPARATOR
Intervention: CT
Number of subjects: 53
Study: 11083748

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (0.05 microgram/kg/min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8853765

Group type: EXPERIMENTAL
Intervention: Mesalazine (Asacol 1.6 g daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Olsalazine (Dipentum 1.0 g daily)
Number of subjects: 15
Study: 1627817

Group type: EXPERIMENTAL
Intervention: XRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRM
Number of subjects: 0
Study: 6378159

Group type: EXPERIMENTAL
Intervention: 1% lidocaine hydrochloride with 1:200,000 epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% bupivacaine hydrochloride with 1:200,000 epinephrine
Number of subjects: 0
Study: 31056954

Group type: EXPERIMENTAL
Intervention: Outdoor Walking Training (OWT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cycle Ergometer Training (CT)
Number of subjects: 16
Study: 29195028

Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mast cell stabilizer (1 mg ketotifen twice daily for three months)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Varicocelectomy followed by mast cell stabilizer (1 mg ketotifen twice daily for three months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 120
Study: 27067196

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP), administered monthly from 6 to 24 months of age.
Number of subjects: 177
Study: 24867434

Group type: EXPERIMENTAL
Intervention: Low perceived required effort
Number of subjects: 120

Group type: COMPARATOR
Intervention: High perceived required effort
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Support available
Number of subjects: 120

Group type: COMPARATOR
Intervention: Support not available
Number of subjects: 120
Study: 22305890

Group type: EXPERIMENTAL
Intervention: Atorvastatin in combination with carboplatin
Number of subjects: 1

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Atorvastatin and carboplatin
Number of subjects: 1
Study: 20561549

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) use group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 18028873

Group type: EXPERIMENTAL
Intervention: Group debriefing (67 participants)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (52 participants)
Number of subjects: 119
Study: 15778928

Group type: EXPERIMENTAL
Intervention: Basal glucose concentration (G (b)) assigned the value of fasting plasma glucose concentration (G (fast))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Basal glucose concentration (G (b)) assigned the value of plasma glucose concentration 180 minutes after the start of the IVGTT (G (180))
Number of subjects: 15
Study: 12835077

Group type: EXPERIMENTAL
Intervention: Novel drug delivery system with coarse dispersion (average particle size 1-150 microm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microemulsion system
Number of subjects: 0
Study: 11391543

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 3 years
Number of subjects: 58
Study: 9164421

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 0
Study: 7970428

Group type: EXPERIMENTAL
Intervention: Captopril-enhanced 99Tcm-MAG3 renal scintigraphy
Number of subjects: 27
Study: 2960494

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 39
Study: 31201949

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 0
Study: 26865083

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% continuous wound infiltration (8 ml/h)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups received intraoperative low-dose ketamine, acetaminophen, NSAIDs, nefopam, and morphine PCA
Number of subjects: 39
Study: 26806502

Group type: EXPERIMENTAL
Intervention: Spironolactone (25‐50 mg)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 22985207

Group type: EXPERIMENTAL
Intervention: 1 μg·kg(‐1) intranasally (group N)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 1 μg·kg(‐1) buccally (group B)
Number of subjects: 62
Study: 21235700

Group type: EXPERIMENTAL
Intervention: Solifenacin (5/10 mg)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 738
Study: 19373213

Group type: EXPERIMENTAL
Intervention: RTGT
Number of subjects: 77

Group type: COMPARATOR
Intervention: CHSC
Number of subjects: 77
Study: 17011500

Group type: EXPERIMENTAL
Intervention: MK-0557, 1 mg/day
Number of subjects: 1661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1661
Study: 15233971

Group type: EXPERIMENTAL
Intervention: 1 minute occlusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 minutes occlusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3 minutes occlusion
Number of subjects: 20
Study: 11189689

Group type: EXPERIMENTAL
Intervention: Recruitment interventions (three increasingly intensive interventions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minority-focused PLCO trial screening center
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study on factors influencing black women's decisions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study on psychosocial factors
Number of subjects: 0
Study: 9299885

Group type: COMPARATOR
Intervention: Normal alleles
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Expanded alleles
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Allele distribution
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: CAG repeat stability
Number of subjects: 111
Study: 8070826

Group type: EXPERIMENTAL
Intervention: Lidocaine prophylaxis (1.5 mg/kg bolus followed by 2 mg/min infusion)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine prophylaxis
Number of subjects: 100
Study: 31647464

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (chemoprevention of KC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 29482983

Group type: EXPERIMENTAL
Intervention: Switch strategy (2 years of tamoxifen followed by 3 years of aromatase inhibitors)
Number of subjects: 3697

Group type: COMPARATOR
Intervention: Upfront treatment (5 years of aromatase inhibitors)
Number of subjects: 3697

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg per day for 5 years)
Number of subjects: 3697

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg per day for 5 years)
Number of subjects: 3697

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg per day for 5 years)
Number of subjects: 3697

Group type: COMPARATOR
Intervention: Switch strategy
Number of subjects: 3697

Group type: EXPERIMENTAL
Intervention: Upfront treatment
Number of subjects: 3697
Study: 29231299

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with dynamic moxibustion
Number of subjects: 55

Group type: COMPARATOR
Intervention: Acupuncture alone
Number of subjects: 55
Study: 24789736

Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy for Primary Care (PST-PC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dietary Education Control (DIET)
Number of subjects: 45
Study: 22149875

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus docetaxel
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab plus docetaxel
Number of subjects: 808
Study: 20698956

Group type: EXPERIMENTAL
Intervention: Stroke volume guided fluid therapy combined with dopexamine (0.5 mcg/kg/min) (SV & DPX group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Stroke volume guided fluid therapy (SV group)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Central venous pressure guided fluid therapy (CVP group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Overall complication rates
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Serum inflammatory markers
Number of subjects: 135
Study: 17668541

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment
Number of subjects: 839

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 839
Study: 16055957

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d) and calcium carbonate (500 mg/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Estradiol implant (25 mg, replaced every 6 mo)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Calcium carbonate (500 mg/d) only (Control for alendronate group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham procedure (Control for estradiol group)
Number of subjects: 26
Study: 11846888

Group type: EXPERIMENTAL
Intervention: RUL ECT at 5 or 2.5 times seizure threshold
Number of subjects: 40
Study: 9973655

Group type: EXPERIMENTAL
Intervention: Ebselen (150 mg b.i.d. for 2 weeks)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 8849539

Group type: EXPERIMENTAL
Intervention: Potential Acuity Meter (PAM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oscillatory Displacement Threshold (ODT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Rodenstock Retinometer (RR)
Number of subjects: 52
Study: 2279644

Group type: EXPERIMENTAL
Intervention: 0.75% sodium tetradecyl sulfate (STD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 1.6% sodium morrhuate (MOR) diluted with 50% dextrose
Number of subjects: 41
Study: 550621

Group type: EXPERIMENTAL
Intervention: diisopropylamine (3 times 200 mg a day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: reserpine (3 times 0.25 mg a day)
Number of subjects: 64
Study: 30522912

Group type: EXPERIMENTAL
Intervention: MRI-transrectal ultrasound (TRUS) fusion targeted biopsy (FUS-TB)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Cognitive registration TRUS targeted biopsy (COG-TB)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: In-bore MRI targeted biopsy (MRI-TB)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 665
Study: 30144819

Group type: EXPERIMENTAL
Intervention: Massage protocol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stress protocol followed by massage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stress protocol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 26897446

Group type: EXPERIMENTAL
Intervention: Extraction angle of 60°
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extraction angle of 90°
Number of subjects: 60
Study: 25048381

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1309

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 1309
Study: 23227155

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RES)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both AER and RES
Number of subjects: 25
Study: 20219763

Group type: COMPARATOR
Intervention: Vitamin D intervention (placebo control)
Number of subjects: 2668

Group type: EXPERIMENTAL
Intervention: Seasonal variation adjustment
Number of subjects: 2668

Group type: EXPERIMENTAL
Intervention: Changes in weight, intake of vitamin D, and physical activity
Number of subjects: 2668
Study: 17714465

Group type: EXPERIMENTAL
Intervention: AH Plus (G1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pulp Canal Sealer EWT (G2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RoekoSeal (G3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GuttaFlow (G4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Negative control (intact crowns)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Positive control (not root filled)
Number of subjects: 100
Study: 16335039

Group type: EXPERIMENTAL
Intervention: Human plasma perfusion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Physiologic saline perfusion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Syntac/Tetric
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Solobond Plus/Arabesk
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Compoglass SCA/Compoglass
Number of subjects: 150
Study: 11991216

Group type: EXPERIMENTAL
Intervention: perindopril 4 mg once daily (n = 42)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: losartan 50 mg once daily (n = 43)
Number of subjects: 85
Study: 9655533

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 10 mg/kg twice daily for 5 days
Number of subjects: 520

Group type: COMPARATOR
Intervention: Cefuroxime axetil 10 mg/kg twice daily for 10 days
Number of subjects: 520
Study: 8732151

Group type: EXPERIMENTAL
Intervention: Bushenhuoxue Tablet (BSHX)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 2652180

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 60029

Group type: EXPERIMENTAL
Intervention: Desoximetasone (0.25%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate (0.1%)
Number of subjects: 30
Study: 31621856

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) adapted program
Number of subjects: 1
Study: 30526053

Group type: EXPERIMENTAL
Intervention: Western instructors (WIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nepalese instructor candidates (NICs)
Number of subjects: 0
Study: 27515294

Group type: EXPERIMENTAL
Intervention: Meniett device (Medtronic Xomed)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 129
Study: 27797997

Group type: EXPERIMENTAL
Intervention: Electronic medication management (eMM) system implemented in paediatric wards, details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified electronic medication management (eMM) system implemented in the second paediatric hospital, details on dosage and duration not specified.
Number of subjects: 0
Study: 25428337

Group type: EXPERIMENTAL
Intervention: Adjunctive Buchang Naoxintong Capsule (NXT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (clopidogrel 75 g)
Number of subjects: 90
Study: 22459724

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for four weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20121658

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (22 or 44 mcg three times weekly)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (44 mcg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Interferon beta‐1a (22 mcg)
Number of subjects: 68
Study: 17540662

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) implantation
Number of subjects: 469

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 469
Study: 17050262

Group type: EXPERIMENTAL
Intervention: Clinician ratings on a battery of 10 neuropsychological tests
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Classification based on standard scores
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Global Deficit Scores (GDS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clinician ratings and deficit scores
Number of subjects: 100
Study: 12598816

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (Alcar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10571496

Group type: EXPERIMENTAL
Intervention: Caring-based counseling
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Time passing
Number of subjects: 242
Study: 8688344

Group type: EXPERIMENTAL
Intervention: PACEBOM
Number of subjects: 459

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 459
Study: 1992304

Group type: EXPERIMENTAL
Intervention: Solution A (rice-syrup solids)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Solution C (glucose-based solution, control)
Number of subjects: 86
Study: 6340973

Group type: EXPERIMENTAL
Intervention: Glucametacin (420 mg daily for 20 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketoprofen (300 mg daily for 20 days)
Number of subjects: 30
Study: 30719536

Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Neural Network (NN)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Flexible Discriminant Analysis (FDA)
Number of subjects: 126
Study: 28060040

Group type: EXPERIMENTAL
Intervention: Cysticidal therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (no cysticidal therapy mentioned)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Single lesion NCC
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Multiple lesion NCC
Number of subjects: 500
Study: 26335906

Group type: EXPERIMENTAL
Intervention: Intraplexus approach
Number of subjects: 26

Group type: COMPARATOR
Intervention: Periplexus approach
Number of subjects: 26
Study: 23369024

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Loxoprofen (180 mg/day)
Number of subjects: 10
Study: 21368088

Group type: EXPERIMENTAL
Intervention: High spatial frequency (SF) gratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low spatial frequency (SF) gratings
Number of subjects: 0
Study: 19587472

Group type: EXPERIMENTAL
Intervention: Ibuprofen 500 mg, three times a day for nine days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Mesalamine 400 mg, three times a day for nine days
Number of subjects: 58
Study: 17765438

Group type: EXPERIMENTAL
Intervention: Brimonidine‐purite 0.15%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Phenylephrine 1%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium hyaluronate 0.1%
Number of subjects: 90
Study: 15466785

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Cyclophosphamide plus cisplatin
Number of subjects: 152
Study: 11772973

Group type: EXPERIMENTAL
Intervention: Terlipressin (3 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Albumin (8 g/l of removed ascites)
Number of subjects: 20
Study: 9882082

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 12.5 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 50 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 8071037

Group type: EXPERIMENTAL
Intervention: iopromide (370 mg I/mL)
Number of subjects: 187

Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 187

Group type: COMPARATOR
Intervention: iohexol (350 mg I/mL)
Number of subjects: 187
Study: 2650531

Group type: EXPERIMENTAL
Intervention: Visible light-activated, fluoride-releasing bonding system
Number of subjects: 22

Group type: COMPARATOR
Intervention: Visible light-activated conventional bonding system
Number of subjects: 22
Study: 241357

Group type: EXPERIMENTAL
Intervention: LF 17-895 (10 mg oral dose)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: LF 17-895 (4 mg intravenous dose)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Pindolol (comparison drug)
Number of subjects: 5
Study: 29265891

Group type: EXPERIMENTAL
Intervention: Spinomed® orthosis
Number of subjects: 34

Group type: COMPARATOR
Intervention: Posture training support (PTS)
Number of subjects: 34
Study: 27626368

Group type: EXPERIMENTAL
Intervention: Surgical treatment (Group 2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nonsurgical treatment (Group 1)
Number of subjects: 62
Study: 26044218

Group type: EXPERIMENTAL
Intervention: Nasotracheal suction mechanical ventilation treatment (test group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Noninvasive positive pressure ventilation (CPAP) treatment (control group)
Number of subjects: 53
Study: 23842830

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization (ER)
Number of subjects: 151